China

This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX
This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX
Endpoints
Hansoh Pharmaceutical
China
IPOs
Hong Kong
Flag link:
FDA's Pazdur encourages Chinese companies to bring low-cost PD-1 drugs to U.S. market
FDA's Pazdur encourages Chinese companies to bring low-cost PD-1 drugs to U.S. market
BioCentury
Richard Pazdur
FDA
China
anti-PD-L1
Flag link:
U.S., China key to GSK's consumer venture with Pfizer
U.S., China key to GSK's consumer venture with Pfizer
Yahoo/Reuters
China
GSK
Pfizer
consumer healthcare
Flag link:
Keytruda nabs key lung cancer nod in China. But are blockbuster sales really attainable?
Keytruda nabs key lung cancer nod in China. But are blockbuster sales really attainable?
Fierce Pharma
Merck
Keytruda
China
advanced non-squamous non-small cell lung cancer
Flag link:
China lists 30 more overseas drugs eligible for Priority Review
China lists 30 more overseas drugs eligible for Priority Review
BioCentury
China
drug approvals
Flag link:
AstraZeneca to help build new life science research cluster in China
AstraZeneca to help build new life science research cluster in China
Fierce Biotech
AstraZeneca
China
R&D
Flag link:
Medtronic launches Shanghai-based medtech incubator
Medtronic launches Shanghai-based medtech incubator
Mass Device
Medtronic
devices
Shanghai
China
device company incubators
Flag link:
Novartis launches COPD inhalers in China
Novartis launches COPD inhalers in China
Drug Delivery Business News
Novartis
COPD
China
Ultibro Breezhaler
Seebri Breezhaler
devices
Flag link:
An AIDS therapy involving parasite injections was discredited. China is reviving it — for cancer
An AIDS therapy involving parasite injections was discredited. China is reviving it — for cancer
Stat
Henry Heimlich
China
malarial therapy
cancer
Flag link:
China proposes 50% reimbursement for chronic disease therapies
China proposes 50% reimbursement for chronic disease therapies
BioCentury
China
reimbursement
chronic disease
Flag link:
Analysts: Keytruda has a blockbuster market not factored into Merck’s forecasts—China
Analysts: Keytruda has a blockbuster market not factored into Merck’s forecasts—China
Fierce Pharma
Merck
Keytruda
immuno-oncology
China
Flag link:
Novo Nordisk Launches Innovation Platform in China
Novo Nordisk Launches Innovation Platform in China
CP Wire
Novo Nordisk
China
innovation
Innovo
Flag link:
Novo Nordisk Launches Innovation Platform in China
Novo Nordisk
China
Flag link:
Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx
Following key late-stage advances, BeiGene puts down $10M to get some discovery projects rolling at Ambrx
Endpoints
BeiGene
China
Ambrx
Flag link:
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China
Pharmaceutical Business Review
Novartis
Cosentyx
China
psoriasis
Flag link:
Ascletis poaches top MSD China executive as its new R&D chief
Ascletis poaches top MSD China executive as its new R&D chief
Fierce Biotech
R&D
China
Ascletis Pharmaceuticals
Flag link:
Gracell raises $85M series B to advance cell therapies
Gracell raises $85M series B to advance cell therapies
BioCentury
Gracell
China
cell therapy
Flag link:
China releases list of rare disease drugs with reduced VAT
China releases list of rare disease drugs with reduced VAT
BioCentury
China
VAT
Rare Diseases
Flag link:
Chinese Immuno-Oncology Company to Raise $282 Million Via Hong Kong IPO
Chinese Immuno-Oncology Company to Raise $282 Million Via Hong Kong IPO
CP Wire
CStone Pharmaceuticals
IPOs
China
Hong Kong
immuno-oncology
Flag link:
China to Cut Value Added Tax on Rare Disease Drugs to 3%
China to Cut Value Added Tax on Rare Disease Drugs to 3%
CP Wire
China
Rare Diseases
VAT
Flag link:

Pages